Evidence map›Paper›PMID 34001106›Full record

ArticleCancer cell international2021

Down-regulated FST expression is involved in the poor prognosis of triple-negative breast cancer.

Sainan Liu, Bin Liu, Qian Zhao, Jikang Shi, Yulu Gu, Yanbo Guo, Yong Li, Yunkai Liu, Yi Cheng, Yichun Qiao and 1 more

Open access · goldAbstract read
In one paragraph

Article in Cancer cell international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.5field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Sainan LiuDepartment of Epidemiology and Biostatistics, School of Public Health, Jilin University, Changchun, 130021, China.
Bin LiuDepartment of Breast Surgery, Second Affiliated Hospital of Jilin University, Changchun, 130021, China.
Qian ZhaoDepartment of Epidemiology and Biostatistics, School of Public Health, Jilin University, Changchun, 130021, China.
Jikang ShiDepartment of Epidemiology and Biostatistics, School of Public Health, Jilin University, Changchun, 130021, China.
Yulu GuDepartment of Epidemiology and Biostatistics, School of Public Health, Jilin University, Changchun, 130021, China.
Yanbo GuoDepartment of Epidemiology and Biostatistics, School of Public Health, Jilin University, Changchun, 130021, China.
Yong LiDepartment of Epidemiology and Biostatistics, School of Public Health, Jilin University, Changchun, 130021, China.
Yunkai LiuInstitute of Translational Medicine, The First Hospital of Jilin University, Changchun, 130021, China.
Yi ChengInstitute of Translational Medicine, The First Hospital of Jilin University, Changchun, 130021, China.
Yichun QiaoDepartment of Epidemiology and Biostatistics, School of Public Health, Jilin University, Changchun, 130021, China. qiaoyichun@jlu.edu.cn.
Yawen LiuDepartment of Epidemiology and Biostatistics, School of Public Health, Jilin University, Changchun, 130021, China. ywliu@jlu.edu.cn.
Jilin University · CNSecond Affiliated Hospital of Jilin University · CN

Funding

Department of Health and Family Planning Commission of Jilin Province 2017Q037Department of Science and Technology of Jilin Province 20180414086GHDepartment of Science and Technology of Jilin Province 2020021577JCNational Natural Science Foundation of China 81702606the Bethune Plan 2020B16
6 · The paper itself

Abstract

backgroundTriple-negative breast cancer (TNBC) is more commonly associated with young patients, featuring high histological grade, visceral metastasis, and distant recurrence. Follistatin (FST) is a secreted extracellular regulatory protein that antagonizes TGF-β superfamily such as activin and TGF-β related superfamily such as bone morphogenetic protein (BMP). The implication of FST in the proliferation, angiogenesis, and metastasis of solid tumors documents good or poor outcome of patients with BC. However, the role of FST in TNBC remains unclear.

methodsData of 935 patients with breast cancer (BC) were extracted from TCGA. Case-control study, Kaplan-Meier, uni-multivariate COX, and ROC curve were utilized to investigate the relationship between FST expression and the clinical characteristics and prognosis of BC. Functional studies were used to analyze the effect of FST expression on proliferation, apoptosis, migration, and invasion of TNBC cell lines. Bioinformatic methods such as volcanoplot, GO annd KEGG enrichment, and protein-protein interactions (PPI) analyses were conducted to further confirm the different roles of FST in the apoptotic pathways among mesenchymal and mesenchymal stem-like cells of TNBC.

resultsData from TCGA showed that low FST expression correlated with poor prognosis (for univariate analysis, HR = 0.47, 95% CI: 0.27-0.82, p = 0.008; for multivariate analysis, HR = 0.40, 95% CI: 0.21-0.75, p = 0.004). Low FST expression provided high predicted value of poor prognosis in TNBC amongst BCs. FST knockdown promoted the proliferation, migration and invasion of BT549 and HS578T cell lines. FST inhibited the apoptosis of mesenchymal cells by targeting BMP7.

conclusionsLow FST expression is associated with poor prognosis of patients with TNBC. FST expressions exhibit the anisotropic roles of apoptosis between mesenchymal and mesenchymal stem-like cells but promote the proliferation, migration, invasion in both of two subtypes of TNBC in vitro. FST may be a subtype-heterogeneous biomarker for monitoring the progress of TNBC.

Indexed as

FollistatinInvasionMigrationPrognosis biomarkerProliferationTriple-negative breast cancer

Identifiers

PMID34001106
PMCPMC8130405
OpenAlexW3161007513

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.